Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Subjects participating in this study will be followed from time of roll-over from the parent
GM T protocol until 15 years after the last GMT infusion, withdrawal of consent, lost to
follow-up, or death, whichever occurs first. Both local and central laboratory evaluations
and safety assessments will be conducted during this trial. In addition, pediatric subjects
will be monitored for growth, development and sexual maturity.

Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.

Inclusion Criteria:

Subjects who meet the following criteria will be eligible to participate in the Long-Term
Follow-Up study:

1. All adult and pediatric subjects who received at least one GM T cells infusion in a
previous Celgene sponsored or Celgene alliance partner sponsored study, and have
discontinued, or completed the post-treatment follow-up period in the parent treatment
protocol, as applicable.

2. Subject (and, parental/legal representative, when applicable) must understand and
voluntarily sign an Informed Consent Form/Informed Assent Form prior to any
study-related assessments/procedures being conducted.

3. Subject is willing and able to adhere to the study visit schedule and other protocol
requirements.

Exclusion Criteria: